+91 789 2456 581 | info@nckpharma.com

Pharma News

Keep updating your pharma knowledge
17 May 2018

Alcon Cares Project 100 commits to reducing cataract blindness globally

Alcon, the global leader in eye care and a division of Novartis, has announced Alcon Cares Project 100, which aims to reduce cataract blindness by providing equipment to perform phaco surgeries. Alcon Cares, a foundation that oversees equipment and product donations to those in need, will give 100 reprocessed Infiniti units to eligible clinics in Asia, Central and South America, and Africa over the next three years, making it one of the largest eye care equipment donations of its kind.

“Cataracts are one of the leading causes of blindness and the World Health Organization recognizes cataract surgery as one of the most cost-effective treatments offered in developing countries. With 100 Infiniti units being placed in underserved markets, thousands of patients will receive the gift of sight. Additionally, hundreds of doctors who will be trained in phaco surgery in those clinics will be able to go on to provide quality care to thousands more.”

-David Endicott, Chairman of Alcon Cares and Chief Operating Officer, Alcon

Phaco is a modern surgery that uses an ultrasound probe to fragment the lens and remove the cataract. The surgery offers a large cost-savings benefit due to its rapid recovery time, as patients can return to full productivity at a much faster rate than other cataract removal surgeries. Phaco is the preferred cataract surgical method in developed countries; however, large-scale implementation of phaco can be challenging in developing countries due to the expense and lack of experienced surgeons.

Alcon is working with partners to select clinics and hospitals that meet specific criteria, including a proficiency in phaco surgeries, an underserved patient population and adequate infrastructure that can sustain an eye care practice.

The goals of the project, which is expected to conclude on December 31, 2020, are to perform at least 200,000 phaco surgeries and train at least 400 doctors. Alcon Cares will work with its partners to collect annual reports to measure the impact of this project.

About Alcon
Alcon is the global leader in eye care. As a division of Novartis, we offer the broadest portfolio of products to enhance sight and improve people’s lives. Alcon is having strong product portfolio, used in conditions like cataracts, glaucoma, retinal diseases and refractive errors.

Leave a Reply

Scale up your Pharma knwledge to Next Level with our Free Content

Case studies & Caselets
Simulation based learning
Online self competency assessment tests 

etc.